Valuation: GENinCode Plc

Market Cap 6.59M 8.81M 7.71M 7.11M 12.51M 837M 12.71M 85.24M 33.15M 413M 33.09M 32.38M 1.43B P/E 2026 *
-1.25x
P/E 2027 * -
Enterprise Value 5.79M 7.74M 6.78M 6.25M 10.99M 735M 11.17M 74.89M 29.12M 363M 29.07M 28.45M 1.25B EV / Sales 2026 *
1.22x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
1 day-2.78%
1 week-5.91%
Current month-5.91%
1 month-12.50%
3 months-16.67%
6 months-57.32%
Current year-63.54%
1 week 0.85
Extreme 0.85
1
1 month 0.8
Extreme 0.8
1.2
Current year 0.8
Extreme 0.8
2.5
1 year 0.8
Extreme 0.8
5.5
3 years 0.8
Extreme 0.8
14
5 years 0.8
Extreme 0.8
48
10 years 0.8
Extreme 0.8
48
Manager TitleAgeSince
Chief Operating Officer 51 06/09/2018
Chief Executive Officer 62 06/09/2018
Director of Finance/CFO 57 01/11/2020
Director TitleAgeSince
Chairman 62 06/09/2018
Director/Board Member 51 06/09/2018
Director/Board Member 65 01/05/2020
Date Insider Type Main position Quantity % Market Cap.
05-06Free

Director

2,535,704 0.3367%
05-06Free

Chief Financial Officer

13,523,757 1.7959%
05-06Free

Founder

30,428,453 4.0407%
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%-5.91%-51.39%-92.55% 8.81M
-3.49%+8.59%+228.87%+338.07% 21.6B
-0.99%-0.36%-41.30%-22.83% 9.51B
+0.57%-6.79%+30.58%+25.50% 6.73B
-5.42%-1.33%+217.37%-29.81% 4.8B
-1.91%-1.96%-34.15% - 4.94B
-3.71%-8.26%-27.41%-35.76% 4.56B
-0.69%-1.80%-25.47%-27.28% 4.06B
-5.61%-10.59%+63.61%+72.24% 3.69B
-2.02%+2.01%-18.84%-40.86% 2.56B
Average -2.61%-2.72%+34.19%+20.75% 6.25B
Weighted average by Cap. -2.59%+0.91%+89.49%+121.71%

Financials

2026 *2027 *
Net sales 4.73M 6.33M 5.54M 5.11M 8.98M 601M 9.13M 61.22M 23.81M 297M 23.77M 23.25M 1.02B -
Net income -5.02M -6.71M -5.88M -5.41M -9.53M -637M -9.68M -64.93M -25.25M -314M -25.21M -24.66M -1.09B -
Net Debt -800K -1.07M -937K -863K -1.52M -102M -1.54M -10.35M -4.02M -50.13M -4.02M -3.93M -173M -
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
07/07/26 GBX 0.8750 -2.78% 5,825,781
06/07/26 GBX 0.9000 0.00% 563,670
03/07/26 GBX 0.9000 -3.23% 6,541,873
02/07/26 GBX 0.9300 -2.11% 603,740
01/07/26 GBX 0.9500 +2.15% 323,121
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.008750GBP
Average target price
0.0750GBP
Spread / Average Target
+757.14%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENI Stock